MELLOW PHARMA
ActiveMELLOW PHARMA has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €246k and a net result of €101k. Equity is growing by ~24.4% per year across the filed fiscal years. Its solvency ranks better than 34% of 31510 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Checked score
Score 2025
66
/ 100
Healthy▼ -34 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100=
Solvency55▼-40
Growth78▲+26
Stability94
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €16k at 30 days acceptable
Liquidity short (current ratio 0.98 against 2.21 in 2024), and 64.4% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 70
Relative position
BE, all sectors
reference
Sector 70
lower
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
35.6%
Return on assets
14.7%
Age of the figures
8 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 16-07-2026, 15 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
15 d early
2024
29 d late
2023
2 d early
2022
5 d early
2021
30 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
13-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€246k▼ 20.6%
2024 · €310k
2021: €108k
2022: €199k
2023: €246k
2024: €310k
2021 → 2025
Total assets
€690k▲ 12.0%
2024 · €616k
2021: €505k
2022: €589k
2023: €631k
2024: €616k
2021 → 2025
Net result
€101k▲ 54.4%
2024 · €66k
2021: €69k
2022: €92k
2023: €48k
2024: €66k
2021 → 2025
Working capital
€-7k
2024 · €95k
2021: €25k
2022: €78k
2023: €72k
2024: €95k
2021 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€108k-€199k▲ 83.7%€246k▲ 23.9%€310k▲ 26.0%€246k▼ 20.6%
Operating result€110k-€142k▲ 28.7%€79k▼ 44.0%€96k▲ 20.6%€142k▲ 48.5%
Net result€69k-€92k▲ 34.3%€48k▼ 47.7%€66k▲ 35.6%€101k▲ 54.4%
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 48% above 2024 and is the highest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €690k
Fixed assets
€426k▼ 3.7%
Current assets
€264k▲ 52.0%
Equity and liabilities €690k
Equity
€246k▼ 20.6%
Debt
€444k▲ 45.0%
The debt ratio rises from 49.7% to 64.4%: debt grows while equity shrinks.
Key figures and ratios
EBITDA
€159k▲
2024 · €112k
Cash flow
€118k▲
2024 · €82k
Solvency
35.6%▼
2024 · 50.3%
Current ratio
0.98▼
2024 · 2.21
Quick ratio
0.98▼
2024 · 2.21
Debt / equity
1.81▲
2024 · 0.99
ROE
41.2%▲
2024 · 21.2%
ROA
14.7%▲
2024 · 10.7%
Interest coverage
32.15▲
2024 · 20.32
Debt
€444k▲
2024 · €306k
Debt ≤ 1 year
€270k▲
2024 · €78k
Debt > 1 year
€173k▼
2024 · €228k
Income taxes
€36k▲
2024 · €25k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€616k€690k▲
Fixed assets21/28€442k€426k▼
Tangible fixed assets22/27€52k€36k▼
Furniture and vehicles24€4k€3k▼
Leasing and similar rights25€48k€33k▼
Financial fixed assets28€390k€390k=
Current assets29/58€174k€264k▲
Amounts receivable within one year40/41€32k€39k▲
Trade receivables40€32k€39k▲
Other amounts receivable41€29€0▼
Cash at bank and in hand54/58€141k€225k▲
Deferred charges and accrued income490/1€961€750▼
Equity and liabilities
Total equity and liabilities10/49€616k€690k▲
Equity10/15€310k€246k▼
Contributions10/11€40k€40k=
Reserves13€270k€206k▼
Distributable reserves133€270k€206k▼
Profit (loss) carried forward14€0€0=
Amounts payable17/49€306k€444k▲
Amounts payable after more than one year17€228k€173k▼
Financial debts170/4€228k€173k▼
Amounts payable within one year42/48€78k€270k▲
Current portion of amounts payable after more than one year42€56k€57k▲
Financial debts43-€46
Credit institutions430/8-€46
Trade debts44€561€635▲
Suppliers440/4€561€635▲
Taxes, remuneration and social security45€20k€46k▲
Taxes450/3€18k€44k▲
Remuneration and social security454/9€2k€2k=
Other amounts payable47/48€2k€166k▲
Accrued charges and deferred income492/3€268€224▼
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€16k€16k▲
Other operating charges640/8€2k€2k▼
Non-recurring operating charges66A€189€0▼
Gross operating margin9900€115k€161k▲
Operating profit (loss)9901€96k€142k▲
Financial income75/76B€0€0▲
Recurring financial income75€0€0▲
Financial charges65/66B€6k€5k▼
Recurring financial charges65€6k€5k▼
Profit (loss) for the period before taxes9903€90k€137k▲
Income taxes67/77€25k€36k▲
Profit (loss) for the period9904€66k€101k▲
Profit (loss) for the period to be appropriated9905€66k€101k▲
Appropriation of the result
Profit (loss) to be appropriated9906€66k€101k▲
Transfer from equity791/2-€64k
Transfer to equity691/2€64k€0▼
To other reserves6921€64k€0▼
Profit to be distributed694/7€2k€165k▲
Return on contributions (dividend)694€2k€165k▲
The notes to these accounts (8 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
16-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Highest result since 2021net €101k ▲54.4%
Operating result €142k, net result €101k, both a record.
29-08
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 29 days late
2024
29-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Weakest financial yearnet €48k ▼47.7%
Net result drops to €48k, the lowest in the series; recovery starts the following year.
31-12
Financial
Equity above €200kEq €246k ▲23.9%
3 profitable years in a row build equity to €246k.
26-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
31-12
Financial
Equity above €150kEq €199k ▲83.7%
2 profitable years in a row build equity to €199k.
30-08
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 30 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Brugge · 1 establishment unit since 2020
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Fazantenlaan 258200 BruggeGround area
900 m²
Building footprint
181 m²
Volume, LiDAR
826 m³
Parcel 31425C0188/00G000, Flanders · tallest building 7.4 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
MELLOW PHARMA
since 20202.308.992.255
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 31425C0188/00G000 | Flanders | 900 m² | 1 · 181 m² | 7.3 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
VERSAKO
BE 0775.268.342
Lichtervelde · Eq €246k
SILENZIO
BE 0463.029.302
Brugge · Eq €246k
Monkey Mask
BE 0772.357.154
Gent · Eq €246k
De Zijp
BE 0829.450.760
Halle · Eq €245k
THE HUB GROUP
BE 0788.459.253
Antwerpen · Eq €247k
Of 5,668 companies in sector 70100 we hold annual accounts for 3,479. 2,336 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded24-09-2020
Fiscal year end31-12
Activities, NACEBEL
70100Activities of head offices
Sources
Crossroads Bank for EnterprisesNational Bank · 5 filingsAddress and cadastre registers
Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.